Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for p53-abnormal endometrial cancer, including uterine serous carcinoma, drawn from the whole corpus: 7 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Distant relapse after early-stage disease despite chemotherapy.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Whether PARP inhibition helps p53-abnormal tumours as it does ovarian cancer.
Low response to immunotherapy in a class that accounts for most deaths.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Endometrial ORR 57.
OS 44.
OS 18.
A milestone in how this cancer is treated.